The health study found medications commonly prescribed for erectile dysfunction are associated with significant reductions in ...

Societal expectations can create barriers that prevent men from seeking out the mental, physical, and sexual help they need.

Motivated is a reliable telehealth platform that provides fast, safe, and effective ED treatment options while also giving ...

Hims & Hers Health Inc. shares tumbled 22% Thursday, on concerns that Amazon.com Inc.’s latest push into healthcare will ...

Hims & Hers (HIMS) fell 22% after Amazon (AMZN) announced it was entering the hair loss and erectile dysfunction treatment ...

And what might you be able to learn from hearing their stories and asking for their advice? NIV Devotions for Men - Week of November 5 Tuesday, 05 November 2024 NIV Devotions for Men - Week of October ...

Overall, Ro Daily Rise Gummies are a convenient, easy-to-take form of tadalafil for people struggling with ED. If you often ...

Hims & Hers Health (NYSE:HIMS) is gearing up to launch an off-patent version of Novo Nordisk's (NVO) (OTCPK:NONOF) older GLP-1 weight loss therapy liraglutide in 2025, CEO of the telehealth ...

A bitter pill swallowed now is better than being blindsided in the future. ‘Admitting the existence of patriarchy is the first step to addressing it, denying it only perpetuates the problem,’ says ...

Direct-to-consumer telehealth company Hims & Hers is defending its sale of compounded glucagon-like peptide agonists, or GLP-1s, even as shortages of the name brand weight loss medications are waning.

Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4. The move comes as patients ...

Allen Lutz, an analyst from Bank of America Securities, maintained the Buy rating on Hims & Hers Health (HIMS – Research Report). The associated price target remains the same with $25.00.